Catheter-based therapies for patients with medication-refractory pulmonary arterial hypertension.
作者信息
Leopold Jane A
机构信息
From the Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
出版信息
Circ Cardiovasc Interv. 2015 Nov;8(11):e003332. doi: 10.1161/CIRCINTERVENTIONS.115.003332.
Abstract
摘要
相似文献
1
Catheter-based therapies for patients with medication-refractory pulmonary arterial hypertension.
Circ Cardiovasc Interv. 2015 Nov;8(11):e003332. doi: 10.1161/CIRCINTERVENTIONS.115.003332.
2
Pulmonary artery denervation reduces pulmonary artery pressure and induces histological changes in an acute porcine model of pulmonary hypertension.
Circ Cardiovasc Interv. 2015 Nov;8(11):e002569. doi: 10.1161/CIRCINTERVENTIONS.115.002569.
3
Letter by Hoeper and Galiè Regarding Article, "Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes: Phase II Results From the Pulmonary Artery Denervation-1 Study".
Circ Cardiovasc Interv. 2016 Jan;9(1):e003422. doi: 10.1161/CIRCINTERVENTIONS.115.003422.
4
Response to Letter Regarding Article, "Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes: Phase II Results From the Pulmonary Artery Denervation-1 Study".
Circ Cardiovasc Interv. 2016 Jan;9(1):e003463. doi: 10.1161/CIRCINTERVENTIONS.115.003463.
5
Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes: phase II results from the Pulmonary Artery Denervation-1 study.
Circ Cardiovasc Interv. 2015 Nov;8(11):e002837. doi: 10.1161/CIRCINTERVENTIONS.115.002837.
6
Pulmonary Artery Denervation by Determining Targeted Ablation Sites for Treatment of Pulmonary Arterial Hypertension.
Circ Cardiovasc Interv. 2017 Oct;10(10). doi: 10.1161/CIRCINTERVENTIONS.117.005812.
7
Perivascular Innervation of the Pulmonary Artery in Human and Swine: A Comparative Study for the Development of an Experimental Model of Denervation.
Bull Exp Biol Med. 2020 Dec;170(2):279-282. doi: 10.1007/s10517-020-05051-w. Epub 2020 Dec 2.
8
Pulmonary artery denervation using catheter-based ultrasonic energy.
EuroIntervention. 2019 Oct 20;15(8):722-730. doi: 10.4244/EIJ-D-18-01082.
9
Pulmonary arterial hypertension: pharmacologic therapies and potential pulmonary artery denervation treatment.
EuroIntervention. 2013 May;9 Suppl R:R149-54. doi: 10.4244/EIJV9SRA25.
10
[Chinese expert advisory on percutaneous pulmonary artery denervation for the treatment of pulmonary hypertension].
Zhonghua Xin Xue Guan Bing Za Zhi. 2024 Jun 24;52(6):647-658. doi: 10.3760/cma.j.cn112148-20231230-00545.
引用本文的文献
1
High-intensity Focused Ultrasound-A New Choice to Conduct Pulmonary Artery Denervation.
J Cardiovasc Transl Res. 2024 Dec;17(6):1353-1364. doi: 10.1007/s12265-024-10531-9. Epub 2024 Jul 6.
2
The progress of pulmonary artery denervation.
Cardiol J. 2022;29(3):381-387. doi: 10.5603/CJ.a2020.0186. Epub 2021 Jan 13.
3
Knockdown of Long Noncoding RNA (lncRNA) AK094457 Relieved Angiotensin II Induced Vascular Endothelial Cell Injury.
Med Sci Monit. 2020 Feb 6;26:e919854. doi: 10.12659/MSM.919854.
4
Overexpression of microRNA-506-3p aggravates the injury of vascular endothelial cells in patients with hypertension by downregulating Beclin1 expression.
Exp Ther Med. 2018 Mar;15(3):2844-2850. doi: 10.3892/etm.2018.5733. Epub 2018 Jan 10.
5
Molecular mechanisms in vascular injury induced by hypertension: Expression and role of microRNA-34a.
Exp Ther Med. 2017 Dec;14(6):5497-5502. doi: 10.3892/etm.2017.5216. Epub 2017 Sep 27.
本文引用的文献
1
Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes: phase II results from the Pulmonary Artery Denervation-1 study.
Circ Cardiovasc Interv. 2015 Nov;8(11):e002837. doi: 10.1161/CIRCINTERVENTIONS.115.002837.
2
Pulmonary artery denervation reduces pulmonary artery pressure and induces histological changes in an acute porcine model of pulmonary hypertension.
Circ Cardiovasc Interv. 2015 Nov;8(11):e002569. doi: 10.1161/CIRCINTERVENTIONS.115.002569.
3
Five-Year outcomes of patients enrolled in the REVEAL Registry.
Chest. 2015 Oct;148(4):1043-54. doi: 10.1378/chest.15-0300.
4
Emerging Concepts in the Molecular Basis of Pulmonary Arterial Hypertension: Part II: Neurohormonal Signaling Contributes to the Pulmonary Vascular and Right Ventricular Pathophenotype of Pulmonary Arterial Hypertension.
Circulation. 2015 Jun 9;131(23):2079-91. doi: 10.1161/CIRCULATIONAHA.114.006980.
5
Interventional and surgical therapeutic strategies for pulmonary arterial hypertension: Beyond palliative treatments.
J Cardiol. 2015 Oct;66(4):304-14. doi: 10.1016/j.jjcc.2015.02.001. Epub 2015 Mar 11.
6
Palliative Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the first 24 patients.
Eur J Cardiothorac Surg. 2015 Mar;47(3):e105-10. doi: 10.1093/ejcts/ezu445. Epub 2014 Dec 4.
7
Balloon dilation atrial septostomy for advanced pulmonary hypertension in patients on prostanoid therapy.
Catheter Cardiovasc Interv. 2015 May;85(6):1066-72. doi: 10.1002/ccd.25751. Epub 2014 Dec 10.
8
Pulmonary arterial hypertension in adults: novel drugs and catheter ablation techniques show promise? Systematic review on pharmacotherapy and interventional strategies.
Biomed Res Int. 2014;2014:743868. doi: 10.1155/2014/743868. Epub 2014 Jun 12.
9
Definitions and diagnosis of pulmonary hypertension.
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D42-50. doi: 10.1016/j.jacc.2013.10.032.
10
Percutaneous interventional therapies for the treatment of patients with severe pulmonary hypertension.
J Am Coll Cardiol. 2014 Feb 25;63(7):611-618. doi: 10.1016/j.jacc.2013.11.022. Epub 2013 Dec 11.
Zotero 插件